A5111032357- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Polyomavirus and related diseases
- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Neuroendocrine Tumor Research Advances
Guangdong Medical College
2023-2025
Background: Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of non-small-cell lung cancer that predominantly affects younger, non-smoking individuals in southern and southeast Asia, where Epstein–Barr virus (EBV) prevalence high. The efficacy safety immunotherapy pLELC, especially second-line settings, remain inadequately explored. Objectives: This study aimed to evaluate the immunotherapy, either alone or combination with chemotherapy, improving progression-free...
This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate 19-9 [CA19-9], and 125 [CA125]) efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer.This multicenter retrospective evaluated who received July 2017 2022. The endpoints were progression-free survival (PFS) overall (OS), as defined by Response Evaluation...
To date, no specific studies have reported the use of dynamic serum tumor markers (STMs) as prognostic factors in patients with advanced non-small-cell lung cancer (NSCLC) who receive first-line immunotherapy. Therefore, it is unclear whether STMs can be used a factor for immunotherapy NSCLC.To elucidate role monitoring response NSCLC. Patients were treated programmed cell death-1/programmed death ligand-1 inhibitors at four Chinese centers.This was multicenter retrospective study.Blood...
ABSTRACT Background: Compared with other lung squamous cell carcinomas (LUSC), pulmonary lymphoepithelioma-like carcinoma (pLELC) is closely associated Epstein–Barr virus (EBV) infections a unique molecular profile and immune microenvironment. This study was thus established to compare the treatment response effectiveness of immunotherapy between pLELC LUSC. Material Methods: We enrolled 31 patients 116 LUSC receiving first-line at three centers in China compared immunotherapy. Propensity...